Sun Pharma rises 1% on CLSA upgrade

Healthcare firm Sun Pharmaceutical Industries gained 1 percent on Wednesday as the foreign research house CLSA upgraded the stock to a buy rating with a target price of Rs 990.

March 13, 2013 / 13:33 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Healthcare firm Sun Pharmaceutical Industries gained 1 percent on Wednesday after the foreign research house CLSA upgraded the stock to a `buy' with a target price of Rs 990 a share.

CLSA expects a strong ramp up in its US business led by expansion in the recently acquired URL Generics.

Caraco Pharma, a subsidiary of Sun Pharmaceutical, acquired Japanese drug maker Takeda Pharmaceuticals' US-based generics subsidiary URL Pharma in December.

This was Sun Pharma's second acquisition in the United States within two months after it decided to buy skin treatment firm Dusa Pharmaceuticals Inc for USD 230 million.

At 11:24 hours IST, shares went up 0.97 percent to Rs 835.40 on Bombay Stock Exchange.

first published: Mar 13, 2013 12:04 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347